Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.46 |
| ▸ | BCL9 | O00512 | 2/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.45 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12236481 | 0.89 | MGLL (0.46) | GPR119PAK1PIK3CDPOLB | |
| SCHEMBL12236480 | 0.89 | MAPK7 (0.48) | GPR119HSD11B1MAPK7BCL9CTNNB1 | |
| SCHEMBL20375412 | 0.86 | GPR119 (0.46) | GPR119HSD11B1HTR2BMAPK7PAK1 | |
| SCHEMBL12236476 | 0.86 | GPR119 (0.48) | GPR119SMN1; SMN2KDM4ECYP2C9 | |
| SCHEMBL12236417 | 0.85 | GPR119 (0.51) | GPR119HSD11B1MAPK7CYP2C9 | |
| SCHEMBL13272803 | 0.82 | GPR119 (0.48) | GPR119PIK3CDCYP2C9 | |
| SCHEMBL12236475 | 0.80 | RBP4 (0.56) | GPR119PIK3CD | |
| SCHEMBL12236468 | 0.79 | GPR119 (0.58) | GPR119PIK3CDCYP2C9 | |
| SCHEMBL12236463 | 0.77 | GPR119 (0.59) | GPR119PIK3CD | |
| SCHEMBL12236446 | 0.77 | GPR119 (0.67) | GPR119CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382204-B1 | PYRIMIDINE DERIVATIVES AS GPCR MODULATORS FOR USE IN THE TREATMENT OF OBESITY AND DIABETES | MERCK SHARP & DOHME (US) | 2018-07-11 | — | — | EP | disclosed |
| US-8722882-B2 | Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes | MERCK SHARP & DOHME CORP. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722882-B2 | Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes | MERCK SHARP & DOHME CORP. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20110263570-A1 | PYRIMIDINE DERIVATIVES AS GPCR MODULATORS FOR USE IN THE TREATMENT OF OBESITY AND DIABETES | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263570-A1 | PYRIMIDINE DERIVATIVES AS GPCR MODULATORS FOR USE IN THE TREATMENT OF OBESITY AND DIABETES | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263570-A1 | PYRIMIDINE DERIVATIVES AS GPCR MODULATORS FOR USE IN THE TREATMENT OF OBESITY AND DIABETES | GPR119, GCGR, GPR65 | GPR119 1/4885HSD11B1 1820/4885HTR2B 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.